Our mission is to

BRIDGE THE CANCER CARE GAP

by advancing revolutionary technologies

Singapore's Ministry of Health approves KYAN's clinical laboratory license to provide the Optim.AI™ functional precision medicine test

Learn More Button

Addressing the Core Challenge of Cancer Treatment

Cancer is not a single disease, but rather a group of diseases.


In total there are more than 100 different types of cancers that are dynamically expressed in each patient.


Identifying combinations therapies at different dosages is necessary when searching for the best cancer treatment.


However, neither humans nor Big Data AI/ML can efficiently solve for large and complex set of predictions.


Our Technology

Our revolutionary technology is a phenotypic response system that efficiently identifies safe and effective drug -dose combination therapies


SMALL DATA AI

Efficiently solves large and dynamic complex systems through a minimum number of tests

Addition Symbol

EXPERIMENTAL BIOLOGY

Prospective experiments that identify the optimal phenotypic response surface across different biological models

SMALL DATA AI

Functional Precision Medicine

Our ex vivo analytic platform, Optim.AI™, empowers oncologists to better guide treatment for patients with truly personalized results

How it works

Computational Analysis


Our computational method maps each patient’s individual results, evaluating all actionable treatments from a 12-drug panel


Report and Insights


Clinicians receive a clear report highlighting predicted drug sensitivity/resistance of standard of care and unique combinations

Liquid/Solid Biopsy


We separate the tumor cells while still fresh so that the cancer can be tested in its current state

Proprietary Ex Vivo Testing


Since any patient sample is limited in cells, we maximize the use with a proprietary drug plate design for proper data fitting



How we are different from standard care and other options

Crowd of Pictogram People
Hospital Prescription Icon

STANDARD THERAPY

SAME treatment for all patients and most will fail, requiring multiple lines of treatment

Pictogram Men Standing
Task List

PRECISION MEDICINE

SMALL chance that patients have identifiable biomarkers matched with therapy (est. < 10%)

Person icon
Numbered List

DRUG SENSITIVITY

LIMITED results when screening single drugs and preselected combinations

UNIQUE data and treatments for each patient's as their own cancer cells are used for drug response analysis

VAST number of regimens are evaluated to maximize finding effective treatment, truly personalizing care

ALL actionable treatments within a drug set can be ranked based on sensitivity and compared, including against standard care

Biopharma Services

Target Icon

New target prioritization

Large search discovery for new targets + combinations

Unlock Private

combination discovery

Explore combination discovery for lead targets

Sine

DOSE

OPTIMIZATION

Identification Icon

Biomarker Identification

Retrospective or prospective studies to support dose optimization within trials


Find biomarker signatures based on phenotypic response curves


Arrow Forming Circle

Revive

Failed Assets

Find new combination partners or companion Dx for assets that failed trials


Our Team

Hugo Saavedra

CEO

Lisa Chow

COO

William Tan

Director, Field Scientist & Customer Management

Manjunatha (Miki) T. A.

Medical Director

Sudha Sruthi

Corporate Development Manager

Masturah Rashid

Head, R&D

Jhin Jieh Lim

Research Scientist

Michael Ching

Lab Manager

Scientific Co-founders

Edward Chow

Principal Investigator, Cancer ​Science Institute of Singapore,

Assoc. Professor and Research ​Director, Pharmacology, ​School of Medicine, NUS

Dean Ho

Provost’s Chair Professor; ​Director, N.1 and WisDM; ​Head, Department of ​Biomedical Engineering,​ NUS

Chih-Ming Ho

UCLA Ben Rich-Lockheed ​Martin Professor Emeritus

U.S. NAE Member

Academia Sinica Academician

C​o-founder of GeneFluidics

Advisors

Wee Joo Chng

Boa​r​d Advisor


St​even Myint

Boa​r​d Advisor


Andreas Voss

Board Advisor

Phal Singh

Chief Financial ​Advisor

Rasha Kandil

Chief Regulatory ​Advisor

Newsroom

Poster on clinical evaluation of combination-specific sub-population T-cell lymphoma presented at

AACR 2023

Annual Meeting

April 2023

KYAN announces partnership with CELLphenomics

April 2023


KYAN Therapeutics and Curie ​Oncology Announce ​Collaboration to Provide ​Personalized Cancer Test

May 2022

Clinical Data on KYAN's ​personalized oncology ​platform presented at the

2021 ASH

Annual Meeting

November 2021

Data on Novel HDACi ​Targeting KRAS-mutated ​Cancers presented at the

AACR-KCA

Joint Conference on Precision ​Medicine in Solid Tumors


No​vember 2021

Publications

PDPA POLICY

In this policy, “KYAN Therapeutics” or “we” refers to KYAN Technologies Pte Ltd, a Singapore company, UEN 202226520H (together with our subsidiaries).

KYAN Therapeutics is committed to ensuring the proper protection of all information assets within our possession, and doing so in accordance with the Singapore Personal Data Protection Act (the “PDPA”), the ​Private Hospitals and Medical Clinics Act, the Ministry of Health’s guidelines, directives and other relevant legislation.

This Personal Data Protection Policy explains how we collect, hold, use, disclose, secure, and otherwise manage all personal information. It describes the types of information we collect and hold, as well as the ​reasons and methods of accessing and correcting such information.

When you provide us with your personal data, directly or indirectly, you expressly grant consent to KYAN Therapeutics to collect, use, and disclose your personal data to all relevant third parties as laid out in our ​Personal Data Protection Policy.

The policy herein serves as a supplement and therefore does not supersede or act as a substitute to any other prior consent that you may have provided to KYAN Therapeutics with regard to your personal data. ​KYAN Therapeutics also reserves all rights granted by the law to collect, use, or disclose your personal data.

What is personal data?

Personal data is any data about an identified individual or an individual who is reasonably identifiable.

Types of Personal Data that may be provided to or collected by KYAN Therapeutics include but are not limited to:

(a) Name;

(b) NRIC, passport or other personal identification number;

(c) Telephone number;

(d) Fax number

(e) Mailing address;

(f) E-mail address; and

(g) any other information relating to the individual that has been provided to KYAN Therapeutics.


How do we collect personal data?

We may collect personal data in any of the following scenarios:-

  • when you submit a form, including but not limited to laboratory request forms
  • when you provide us with your tissue specimens or any other organic materials such that it is linked with other data in a way that you can be identified
  • when you interact with our staff, including customer service officers, phlebotomists, medical technologists and other KYAN Therapeutics representatives via telephone calls (which may be recorded), letters, fax, ​in-person meetings, and email
  • when our CCTV cameras capture your images while you are in our premises, or when you attend events hosted or sponsored by us during which photographs or videos are taken by us or our representatives
  • when you use our services provided through online platforms, such as our website, including any other online platforms
  • when you request that we contact you, be included in an email or other mailing list, or when you respond to our request for additional personal data as part of our promotions or other initiatives
  • when we receive your personal data from referral parties, public agencies, your employer, or any other third party
  • when you interact with us on our websites, your information may be automatically recorded on our server logs from your browser. E.g. We may employ cookies in order for our server to recognise a return visitor ​as a unique user.
  • when you submit your personal data to us for any other reasons


For what purposes do we use and disclose personal information?


KYAN Therapeutics uses the personal information it collects and holds to:

  • contact individuals to respond to enquiries, to follow up, for authorisation in relation to any service provided
  • enable the provision of education and training in the health profession
  • effectively administer, manage, monitor and improve our services
  • planning, evaluation and complaint-handling
  • communicate with individuals by various means about our available services
  • charging and billing
  • verify an individual’s identity to proceed with sample processing
  • comply with quality assurance or clinical audit activities
  • undertake accreditation activities
  • respond to feedback or customer query
  • address liability indemnity arrangements and reporting
  • compilation or analysis of statistics relevant to services provided


We may also use personal data in circumstances where we are required or authorised by law to do so or where we otherwise have consent of the individual or their representative.

To whom do we disclose personal information?

By contacting or dealing with us, you herein agreed unilaterally that we may disclose an individual’s personal information to the following third parties (including but not limited to) to other health service providers ​involved in the individual’s treatment or diagnostic services


How do we store and secure personal information?

We store personal and health information in electronic form.


The security of personal and health information is very important to us and we take reasonable steps to protect it from misuse, interference and loss and from unauthorised access, modification or disclosure.


Some of the ways we do this include:

  • requiring our staff to maintain confidentiality
  • implementing document storage security
  • imposing security measures for access to our computer systems
  • providing a discreet environment for confidential discussions
  • allowing access to personal and health information only where the individual seeking access to their own information has satisfied our identification requirements


Personal and health information is retained for the period of time determined by KYAN Therapeutics and/or stipulated by law after which it is de-identified or disposed of in a secure manner.

How do we keep personal information accurate and up-to-date?

We take all reasonable steps to ensure that the personal information we collect is accurate, complete and up-to-date, and also when we use or disclose it, that it is relevant.


However, the accuracy of that information depends largely on the quality of the information provided to us.


How can personal information we hold be accessed?

Individuals have a right to access the personal information that KYAN Therapeutics holds about them. We will give access to an individual’s personal information in the form they request.


However, if the situation doesn’t permit us doing so, we will, with reasonable means, provide alternative means of access or discuss how access can be given through a mutually agreed intermediary.

We will disclose the personal information and give access to the individual’s Authorized representative or legal adviser whom we have been given written authority to do so.

Please be aware that if your personal data has been provided to us by a third party (e.g. your doctor or employer), you need to contact that individual or organization directly if you have any related query or ​complaint.

How to contact our Data Protection Officer?

If there are any questions or feedback relating to one’s Personal Data or this policy; or a party would like to withdraw one’s consent to use of one’s Personal Data as set out in this policy; or a party would like to obtain ​access and/or make corrections of Personal Data records, please contact our Data Protection Officer by emailing dpo@kyantherapeutics.com.

Contact Us

Pin

1 Research Link, #05-45, Singapore 117604

Message Glyph Icon

admin@kyantechnologies.com

Illustration of Telephone

+65 6974 0426

蓝白领英社交媒体icon

Connect with us on LinkedIn

Clock Line Icon

Laboratory Hours:

Monday to Friday

9:00 am to 6:00 pm

Closed on Weekend & Public Holidays

KYAN Technologies Pte Ltd is licensed by the Ministry of Health (Singapore) as a Clinical Laboratory

HCI License Number: L/23I0025/CLB/001/232





© 2023 KYAN Technologies Pte Ltd. All Rights Reserved